A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)

Completed · Phase 3 · Has a placebo group

Conditions studied: ADHD

In brief

FOCUS (Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol) is a Phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel- group trial to assess the efficacy and safety of solriamfetol in adults with ADHD.

Key facts

Study ID
NCT05972044
Run by
Axsome Therapeutics, Inc.
People needed
516
Starts
2023-07-06
Expected to finish
2025-03-14
Last updated by the study team
2026-02-10

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.